![]() |
|
|
My Amedeo
FAQ
Privacy
About
|
|
|||||||||
Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK. |
| Ovarian Neoplasms |
|
Free Subscription
1 BMC Cancer |
Retrieve available abstracts of this week’s articles:
HTML format |
| Single Articles |
AMEDEO Ovarian Neoplasms is free of charge.
Retraction Note: Repression of LncRNA PART1 attenuates ovarian cancer cell
viability, migration and invasion through the miR-503-5p/FOXK1 axis.
BMC Cancer. 2026;26:105.
PubMed
T-cell receptor-like chimeric antigen receptor T cells targeting mesothelin: A
first-in-human dose-escalation trial for platinum-resistant advanced ovarian
cancer.
Cancer. 2026;132:e70279.
PubMed
Abstract available
Cytoplasmic SIRT1 enhances the stemness of polyploid giant cancer cells by
promoting beta-catenin protein stability and nuclear accumulation in ovarian
carcinoma upon neoadjuvant chemotherapy.
Cancer Lett. 2025 Dec 1:218193. doi: 10.1016/j.canlet.2025.218193.
PubMed
Abstract available
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade
Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners
Trial (GOG 3026).
J Clin Oncol. 2026;44:153-163.
PubMed
Abstract available
Thank you for your interest in scientific medicine.